Abstract. The regulation of human Factor IX.
IXa was bound to ATIII. Organ distribution studies with '25I-Factor IXa demonstrated that most ofthe radioactivity was in the liver. These studies suggest that Factor IXa binds to at least two classes ofbinding sites on endothelial cells. One site apparently recognizes both Factors IX and IXa, but not Factor X, Factor Xa, prothrombin, or thrombin. The other site recognizes thrombin, Factor Xa, and Factor IXa, but not the zymogen forms of these clotting factors. After this binding, Factor IXa is bound to ATIII and the complex is cleared from the circulation by hepatocytes. introduction Factor IX is a vitamin K-dependent coagulation protein that can be activated by both the intrinsic and extrinsic pathways (1) . Localization of the reactions of the coagulation cascade to the site of vascular injury and the regulation of the activated coagulation factors are important in thrombosis and hemostasis. Recently, Factors IX and IXa (the activated form of Factor IX) were shown to bind to the same site on endothelial cells in tissue culture (2, 3) . Factor X, prothrombin, and thrombin did not bind to this endothelial cell site. Endothelial cell binding may serve to localize clot-promoting activity, as bound Factor IXa has at least three times the procoagulant activity of Factor IXa in solution (3) .
Relatively little is known about the regulation of Factor IXa by the plasma proteinase inhibitors, other than antithrombin III (ATIII).' Bovine and human Factor IXa have been shown to react slowly with ATITI, forming a stable 1:1 stoichiometric complex. This reaction is greatly accelerated in the presence of heparin (4) (5) (6) (7) . The reactions ofFactor IXa with a2-macroglobulin (a2M) and aI-proteinase inhibitor (aIPI) have not been described.
The present studies were undertaken to examine the regulation of human Factor IXa in vivo. The distribution of '251-Factor
IXa among the plasma proteinase inhibitors in human plasma in vitro was examined by sodium dodecyl sulfate-(SDS-) polyacrylamide gel electrophoresis and by IgG-antiproteinase inhibitor-Sepharose beads. These results were compared with those obtained from mouse plasma, and the in vivo regulation of Factor IXa was then studied using our previously described mouse model. We have recently shown that Factor Xa binds to an endothelial cell thrombin-binding site; this binding alters the proteinase inhibitor specificity of Factor Xa such that a2M is the primary in vivo inhibitor of Factor Xa, whereas a1PI is the primary in vitro inhibitor of Factor Xa (8) . In light of these results, the endothelial binding of Factor IXa and the possible role ofthis binding in the regulation ofFactor IXa were examined in vivo in our mouse model.
Methods
Reagents. Reagents were obtained as previously described (8) .
Proteins. Human Factor IX was purified as previously described (9) . Human prothrombin and Factor X were prepared by the method of Miletich et al. (10) . Human a-thrombin (specific activity 2,700 U/mg), DIP-thrombin, Factor Xa, and DIP-Factor Xa were prepared as previously described (8, 11, 12) . Diisopropylfluorophosphate (20 mM) failed to inhibit Factor IXa, even after reaction for 6 or 24 h; this is consistent with previous studies (6) . Human Factor XIa was prepared as described by Chung et al. (9) and used to activate Factor IX as previously described (13) . Activation was 80-85% complete by 90 min, as determined by SDS-polyacrylamide gel electrophoresis under reducing conditions. a2M, ATIII, and ajPI were purified from human plasma as previously reported (11, 14, 15) . Mouse ATIII was prepared essentially as described for human ATIII (1 1).
Trypsin was purchased from Worthington Biochemicals (Freehold, NJ) and was 70% active, as determined by active site titration (16) .
Trypsin complexes of a2M, a1PI, and ATII were prepared as previously described (8) .
Protein concentration. The concentrations of purified proteins were determined using the extinction coefficients and molecular weights previously reported (6, 10, 11, (17) (18) (19) (20) (21) (22) (23) .
Protein radiolabeling. Human a2M, a1PI, and ATIII, and mouse ATIII were radiolabeled with 1251 by the solid state lactoperoxidase method (24) . Radioactivity was measured in a gamma counter (AW14-120; Scientific Products, American Hospital Supply Corp., McGaw Park, IL). Proteins were labeled to specific radioactivities of 1,000-2,000 cpm/ ng and assayed for activity. a2M was assayed by the method of Ganrot (25) . a1PI was assayed as described by Dietz et al. by measuring the inhibition of the hydrolysis of a-N-benzoyl-DL-arginine-p-nitroanilide by trypsin (26) . ATIII activity was determined as the inhibition of the thrombin-catalyzed hydrolysis of the chromogenic substrate S-2238 (27) . In all cases, proteins retained at least 95% activity after radiolabeling.
Human Factor IX was radiolabeled with 1251 using Iodobeads (Pierce Chemical Co., Rockford, IL) in 50 mM Tris-HCl, 0.15 M NaCl, pH 7.4. Typically, 100 Ag Factor IX was incubated with 1.5 mCi 1251I and two beads at room temperature for 30 min with mixing. Specific radioactivities of 1,000-1,500 cpm/ng were routinely obtained. The radiolabeled Factor IX displayed activity identical to that of the unlabeled Factor IX, both species being 80-85% activated by Factor XI. in the presence of Ca"t ions, as assessed by SDS-polyacrylamide gel electrophoresis under reducing conditions.
Polyacrylamide gel electrophoresis. SDS-polyacrylamide gel electrophoresis of purified protein samples was performed using 5 and 7.5% acrylamide slab gels as described by Wycoff et al. (28) . SDS-polyacrylamide gel electrophoresis of plasma samples was performed on 5% slab gels according to the method of Weber and Osborn (29) . 25 (8) . The beads were characterized by incubating 50 ,ul of the resultant IgG-Sepharose preparations with 1-500 jg '25I-labeled human a2M, a1PI, and ATIII, and mouse ATIII, or with the corresponding '251-proteinase inhibitor-trypsin complex in 500 Ml of 50 mM Tris-HCI, 0.15 M NaCl, 60 mg/ml bovine serum albumin, pH 7.40, at 37°C for 2 h with constant mixing in a series of saturation curves. The tubes were then centrifuged in an Eppendorf microcentrifuge. The supernatants were removed and the beads were washed three times with cold Tris buffer (1 ml each). The bottoms of the tubes were cut offand the radioactivity content in beads, supernatants, and washes was determined. Under the conditions chosen for the experiments described below, 80-900% of the applied '251-labeled proteinase inhibitors bound to the corresponding IgG-Sepharose, with 1.5% nonspecific binding, as determined by incubating the noncorresponding inhibitors with a given IgG-Sepharose sample. Plasma elimination studies. Plasma elimination studies of '25I-Factor IX and '25I-Factor IX. (0.5 to I ug) alone or in the presence of large molar excesses of unlabeled proteins were performed in CD-1 female mice, as previously described (8) . To examine the distribution of Factor IX. between the plasma and the cellular elements of blood, 125I-Factor IX. was injected and 800 Ml of blood was collected after 5 min into 0.1 vol 3.8% sodium citrate. The sampled blood was centrifuged at 10,000 g for 10 min at 4VC to pellet the cellular elements and the supernatant plasma was removed with a pipette. The cellular pellet was washed three times with 1 ml cold 0.05 M Hepes, 0.15 M NaCl, pH 7.40, and the radioactivity content of the plasma, washes, and the cellular pellet was determined. In some plasma elimination studies, duplicate samples were taken at each time point. One sample was counted in a gamma counter, the other was drawn into 0.1 vol 3.8% sodium citrate and centrifuged immediately at 4VC. The plasma was then denatured immediately for SDS-gel electrophoresis. In general, studies were performed at least four times.
Tissue distribution studies. Organ distribution studies were performed as previously described after injection of 5 1g of I251-ligand (30) .
Results
Reaction ofFactor IXa with purifiedplasma proteinase inhibitors. 125i-Factor IX is biphasic (Fig. 2 A) , with an initial rapid dis- (Fig. 2 A) , thus mediating against a rapidly clearing subpopulation of modified Factor IX or contaminants. A 2,000-fold molar excess of unlabeled Factor IX inhibited the clearance of labeled Factor IX, prolonging the half-life of '251I-Factor IX from 2 to 10 min (Fig.   2 ). These results suggest that Factor IX is rapidly cleared from the circulation, probably owing to endothelial cell binding as previously described in vitro (3) . The slow late phase ofclearance probably results from equilibration of the injected Factor IX with the murine Factor IX pool. To establish the specificity of this clearance process, competition experiments were performed with Factor X and prothrombin. Even at a 2,000-fold molar excess, neither species inhibited the clearance of '251-Factor IX (Fig. 2 A) . Competition experiments were also performed with DIP-Factor Xa and DIP-thrombin, with no inhibition of the clearance of '251I-Factor IX, even at 2,000-fold molar excesses (Fig. 2 B) .
Plasma elimination of Factor IXa. The clearance of 125i-Factor IXa was rapid and biphasic (Fig. 3 A) . To further characterize the clearance of Factor IX., competition experiments were performed with unlabeled Factor IX, Factor X, prothrombin, DIP-Factor Xa, and DIP-thrombin (Fig. 3, A and B incubated under similar conditions in the absence of the inhibitor. This contrasts markedly with trypsin, which in 15 min is completely inactivated at a I mM concentration of diisopropylfluorophosphate. Thrombin is also rapidly inhibited under these reaction conditions (31) . Therefore, it was impossible to study the clearance of DIP-Factor IXa.
The possibility that the cellular elements of blood are in- vol sodium citrate, separating the plasma and cellular elements as described in Methods, and determining the radioactivity content of each. The cellular pellet contained 0.4% of the recovered radioactivity; the remaining 99.6% was in the plasma. The role ofthe plasma proteinase inhibitors in the catabolism of Factor IXa was investigated using trypsin complexes of a2M and aPI, and ATIII-thrombin. The clearance pathways for proteinase complexes of these inhibitors have been characterized in mouse (1 1, 14, 15) . At a 2,000-fold molar excess, a2M-trypsin failed to inhibit the clearance of Factor IXa (Fig. 4) . At 2,000-fold molar excesses, both ATIII-thrombin and alPI-trypsin inhibited the clearance of '251-Factor IXa, with a1PI-trypsin providing somewhat poorer competition. These results are consistent with the clearance of proteinase complexes of ATIII and a1PI by the same hepatocyte receptor (15) . To characterize further the proteinase inhibitor-dependent phase of Factor IXa clearance, complexes of human ATIII-'251-Factor IXa were prepared and used in clearance studies (Fig.  5) . The clearance of ATIII-'251-Factor IXa was extremely rapid (50% clearance in 1.5 min). The clearance of ATIII-'251-Factor IXa was inhibited by 2,000-fold molar excesses of ATIII-thrombin and to a slightly lesser degree by a1PI-trypsin.
Organ distribution of l2SI-Factor IX and "2I-Factor IXa.
Radiolabeled Factor IX or Factor IXa was injected intravenously. The distributions of radioactivity at 2 and 20 min are shown in Table III . Both species are found predominantly in the liver.
In vivo distribution of '25I-Factor IXa among the plasma proteinase inhibitors. A plasma sample obtained 2 min after the injection of 1251I-Factor IXa was subjected to SDS-polyacrylamide gel electrophoresis (Fig. 1, lane j Table IV . A duplicate plasma sample was incubated with IgGanti-ATIII-Sepharose beads, and the distribution of '251-Factor IXa was calculated (Table IV ). These results demonstrate that nearly 60% of the recovered '251I-Factor IXa is in the form of the complex with ATIII after 2 min, yielding a calculated rate of inhibition of -0.1 ,ug human Factor IX,/ml plasma per min, assuming a plasma volume of -1.5 ml in the mouse (14) .
Discussion
These studies were undertaken to elucidate the catabolism of Factor IXa. Relatively little is known about the reaction of Factor IXa with the plasma proteinase inhibitors, except for ATIII. Factor IXa reacts slowly with ATIII in the absence of heparin (4) (5) (6) (7) . The reactions of Factor IXa with a2M and a1PI have not been described. These results were confirmed using Factor IXa and the purified plasma proteinase inhibitors. The inhibition of Factor IXa by ATIII was slow in the absence of heparin. In the presence of heparin (10 U/ml) the reaction was essentially 100% complete by I min. There was no evidence of complex formation with either a1PI or a2M, even after 2 h incubation with Factor IX,.
In vitro studies with human and mouse plasma confirmed the results obtained with the purified inhibitors, as ATIII was shown to inhibit >60% ofthe Factor IXa by 2 h, with no evidence of Factor IXa bound to either a2M or a1PI. These results also rule out the possibility of proteinase transfer to a2M, as described This discrepancy may be due to cell damage or to loss of the binding site during preparation of the cells for cell culture. These results, together with the clearance and competition studies with Factor IX, suggest that there is at least one class of endothelial cell binding sites that recognizes the activated species Factors IXa and Xa and thrombin, but not the zymogen forms, Factor IX, Factor X, and prothrombin. The nature of the in vivo thrombin binding site is unclear. One class of endothelial cell thrombin site is thrombomodulin. The binding of thrombin to thrombomodulin alters the substrate specificity of thrombin, since the cleavage of fibrinogen and Factor V by thrombin bound to thrombomodulin is drastically reduced (33) . However, thrombin bound to thrombomodulin activates protein C at least 100-fold faster than does free thrombin (34) . From the data obtained to date (2, 3, 8, 33) , there is no evidence that thrombomodulin is the binding site for Factor Xa or Factor IXa, and it seems from the present work that there are at least two classes of Factor IXa binding sites. From all these observations it seems likely that there are several classes of endothelial binding sites that bind the vitamin K-dependent proteinases.
The possibility that the cellular elements of blood may be involved in the catabolism of Factor IXa was investigated by separating the plasma and cellular elements from an in vivo blood sample by centrifugation. The plasma fraction contained 99.6% of the recovered radioactivity, indicating that the cellular elements of blood, such as platelets and leukocytes, are not involved in the regulation of Factor IXa.
The role ofthe plasma proteinase inhibitors in the catabolism of Factor IXa was examined by competition experiments with large molar excesses of unlabeled a2M-trypsin, a1PI-trypsin, and ATIII-thrombin complexes. The clearance pathways for proteinase complexes of these proteinase inhibitors have been well studied (11, 14, 15) , and it has been found that proteinase complexes of ATIII and ajPI are cleared by the same receptor on hepatocytes (15) . The clearance of '251I-Factor IX2 was not inhibited by a large molar excess of a2M-trypsin, indicating that a2M is not involved in the in vivo catabolism of Factor IX2.
ATIII-thrombin and a1PI-trypsin inhibited the clearance of '25I-Factor IX2, with a1PI-trypsin providing somewhat poorer competition. These results are consistent with the clearance of a1PI-and ATIII-proteinase complexes by the same hepatocyte receptor, with a1PI-trypsin complexes clearing with a longer half-time of elimination, as previously described (15) . To characterize further the proteinase inhibitor-dependent phase of Factor IX, catabolism, clearance studies were performed with ATIII-'25I-Factor IX, complexes. The clearance of these complexes was extremely rapid (50% clearance in 1.5 min) and was inhibited by large molar excesses of unlabeled ATIII-thrombin, and to a slightly lesser extent by aPI-trypsin, consistent with the results described above.
Organ distribution studies with 251I-Factor IX or '251-Factor IXa indicate that most of the recovered counts are in the liver, an organ rich in endothelium, and also the site of binding of ATIII-proteinase complexes.
The distribution ofFactor IXa among the plasma proteinase inhibitors in vivo was also examined by SDS-polyacrylamide gel electrophoresis and IgG-antiproteinase inhibitor-Sepharose beads. These experiments demonstrate that nearly 60% of the recovered '251-Factor IXa was in the form of the ATIII complex after 2 min, whereas the in vitro inhibition of Factor IX2 is considerably slower. From the data obtained in vitro in mouse and human plasma and in vivo in the mouse, we calculated the rate of inhibition of Factor IX2 by ATIII. studies that compared the reactivity of human Factor X, to that of ATIII from both species (8) .
In summary, our data suggest that there are at least two classes of Factor IX binding sites in vivo. One class of sites apparently binds both Factor IX and Factor IXa, while the other class binds the activated forms of prothrombin, Factor X, and Factor IX.
